ORIC Pharmaceuticals (STU:4TZ) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is ORIC Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ORIC Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2024 was €-27.00 Mil. ORIC Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Therefore, ORIC Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, ORIC Pharmaceuticals's current FCF Yield % is -26.11%.

The historical rank and industry rank for ORIC Pharmaceuticals's FCF Margin % or its related term are showing as below:

STU:4TZ's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.165
* Ranked among companies with meaningful FCF Margin % only.

ORIC Pharmaceuticals FCF Margin % Historical Data

The historical data trend for ORIC Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ORIC Pharmaceuticals FCF Margin % Chart

ORIC Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

ORIC Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of ORIC Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, ORIC Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ORIC Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ORIC Pharmaceuticals's FCF Margin % falls into.

Save Embed

;

Save Embed

;

ORIC Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ORIC Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-108.727	/	0
	=	%

ORIC Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-27.001	/	0
	=	%

ORIC Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of ORIC Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ORIC Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ORIC Pharmaceuticals Inc (STU:4TZ) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ORIC:USA 4TZ:Germany

Address

240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080

Website

https://www.oricpharma.com

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

ORIC Pharmaceuticals Headlines

No Headlines